☰

Deric L. Wheeler, Ph.D. - Publications

Affiliations: 
2004 University of Wisconsin, Madison, Madison, WI 
Area:
Oncology, Cell Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

106 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan YC, Cho H, Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, et al. Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. Iscience. 26: 107302. PMID 37554452 DOI: 10.1016/j.isci.2023.107302  0.325
2023 Kostecki KL, Iida M, Wiley AL, Kimani S, Mehall B, Tetreault K, Alexandridis R, Yu M, Hong S, Salgia R, Bruce JY, Birge RB, Harari PM, Wheeler DL. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head & Neck. PMID 36939040 DOI: 10.1002/hed.27340  0.387
2022 Toulany M, Iida M, Lettau K, Coan JP, Rebholz S, Khozooei S, Harari PM, Wheeler DL. Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 174: 92-100. PMID 35839938 DOI: 10.1016/j.radonc.2022.07.008  0.307
2022 Iida M, McDaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, Longhurst C, Bruce JY, Hong S, Salgia R, Wheeler DL. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. Bmc Cancer. 22: 447. PMID 35461210 DOI: 10.1186/s12885-022-09511-6  0.431
2021 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Retraction. Science Signaling. 14: eabn0168. PMID 34752142 DOI: 10.1126/scisignal.abn0168  0.576
2020 Srivastava S, Pang KM, Iida M, Nelson MS, Liu J, Nam A, Wang J, Mambetsariev I, Pillai R, Mohanty A, McDaniel N, Behal A, Kulkarni P, Wheeler DL, Salgia R. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. Iscience. 23: 101692. PMID 33196021 DOI: 10.1016/j.isci.2020.101692  0.33
2020 Tiwari A, Iida M, Kosnopfel C, Abbariki M, Menegakis A, Fehrenbacher B, Maier J, Schaller M, Brucker SY, Wheeler DL, Harari PM, Rothbauer U, Schittek B, Zips D, Toulany M. Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. Cancers. 12. PMID 33003386 DOI: 10.3390/cancers12102795  0.33
2020 McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, ... ... Wheeler DL, et al. AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32439698 DOI: 10.1158/1078-0432.Ccr-19-3142  0.434
2020 Iida M, Harari PM, Wheeler DL, Toulany M. Targeting AKT/PKB to improve treatment outcomes for solid tumors. Mutation Research. 111690. PMID 32120136 DOI: 10.1016/J.Mrfmmm.2020.111690  0.481
2019 Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, et al. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 8: 49. PMID 31484920 DOI: 10.1038/s41389-019-0159-6  0.399
2019 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Molecular Cancer Therapeutics. 18: 868. PMID 30936412 DOI: 10.1158/1535-7163.MCT-18-1183  0.682
2019 McDaniel NK, Iida M, Nickel KP, Rodems TS, Swick AD, Prabakaran PJ, Eckers-Kubatzke JC, Welke NB, Kranjac C, Schulz AE, Kimple RJ, Salgia R, Wheeler DL. Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A128  0.499
2018 Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. PMID 30518873 DOI: 10.1038/S41388-018-0572-X  0.664
2018 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Wheeler DL, et al. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099. PMID 30510088 DOI: 10.1158/1078-0432.Ccr-18-3194  0.66
2018 Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77]. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 30442378 DOI: 10.1016/J.Radonc.2018.10.011  0.722
2018 McDaniel NK, Cummings CT, Iida M, Hulse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, ... ... Wheeler DL, et al. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics. PMID 30093568 DOI: 10.1158/1535-7163.Mct-17-1239  0.536
2018 Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 9: 19793-19806. PMID 29731983 DOI: 10.18632/Oncotarget.24857  0.325
2018 Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma. Cell Death & Disease. 9: 5. PMID 29305574 DOI: 10.1038/S41419-017-0029-0  0.479
2018 Abbariki M, Toulany M, Iida M, Morgan A, Nickel K, McDaniel N, Kang G, Li C, Harari P, Wheeler D. Abstract 846: Co-targeting of Axl and MerTK improves radiation response in HNSCC Cancer Research. 78: 846-846. DOI: 10.1158/1538-7445.Am2018-846  0.463
2018 McDaniel NK, Cummings CT, Brand TM, Iida M, Hulse J, Pearson HE, Orbuch RA, Ondracek OJ, Davies KD, Gill P, Wang X, Frye SV, Earp HS, Kimple RJ, Harari PM, ... ... Wheeler DL, et al. Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A140  0.538
2017 Toulany M, Maier J, Iida M, Rebholz S, Holler M, Grottke A, Jüker M, Wheeler DL, Rothbauer U, Rodemann HP. Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells. Cell Death Discovery. 3: 17072. PMID 29090098 DOI: 10.1038/Cddiscovery.2017.72  0.334
2017 Pearson HE, Iida M, Orbuch RA, McDaniel NK, Nickel KP, Kimple RJ, Arbiser J, Wheeler DL. Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol. Molecular Cancer Therapeutics. PMID 29054984 DOI: 10.1158/1535-7163.Mct-17-0384  0.528
2017 Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, Bruce JY, Wheeler DL, Kimple RJ. Co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC. Molecular Cancer Therapeutics. PMID 28446642 DOI: 10.1200/Jco.2017.35.15_Suppl.E17509  0.468
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10. PMID 28049763 DOI: 10.1126/Scisignal.Aag1064  0.78
2017 Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Iida M, Wheeler DL, Nickel KP, Bruce JY, Kimple RJ. Abstract 51: Potential and challenges in co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC Clinical Cancer Research. 23: 51-51. DOI: 10.1158/1557-3265.Aacrahns17-51  0.476
2017 Toulany M, Ilda M, Wheeler DL, Rodemann HP. Abstract B44: Dual targeting of PI3K and MEK impairs DNA double-strand break repair as a relevant mechanism for radioresistance of K-RAS mutated non-small cell lung cancer Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B44  0.382
2017 Black NK, Iida M, Rodems TS, Brand TM, Kimple RJ, Wheeler DL. Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC Cancer Research. 77: 4176-4176. DOI: 10.1158/1538-7445.Am2017-4176  0.756
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Abstract 3333: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor Cancer Research. 77: 3333-3333. DOI: 10.1158/1538-7445.Am2017-3333  0.712
2016 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran P, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Molecular Cancer Therapeutics. PMID 27422810 DOI: 10.1016/S0959-8049(16)32810-6  0.773
2016 Toulany M, Iida M, Keinath S, Iyi FF, Mueck K, Fehrenbacher B, Mansour WY, Schaller M, Wheeler DL, Peter Rodemann H. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Oncotarget. PMID 27248324 DOI: 10.18632/Oncotarget.9670  0.389
2016 Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL. Adaptive responses to antibody based therapy. Seminars in Cell & Developmental Biology. 50: 153-63. PMID 26808665 DOI: 10.1016/J.Semcdb.2016.01.001  0.753
2016 Flanigan BG, Iida M, Brand TM, Wheeler DL. Abstract 247: Understanding the role of tyrosine 1101 in the nuclear translocation of the epidermal growth factor receptor Cancer Research. 76: 247-247. DOI: 10.1158/1538-7445.Am2016-247  0.764
2015 Singh A, Singh A, Bauer SJ, Wheeler DL, Havighurst TC, Kim K, Verma AK. Genetic deletion of TNFα inhibits ultraviolet radiation-induced development of cutaneous squamous cell carcinomas in PKCε transgenic mice via inhibition of cell survival signals. Carcinogenesis. PMID 26586792 DOI: 10.1093/Carcin/Bgv162  0.633
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Wheeler DL, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648  0.7
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  0.758
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294  0.783
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.Mct-13-1021  0.777
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.Mct-13-0109  0.707
2014 Villaflor VM, Wheeler D, Iida M, Vidwans S, Turski M, Brand TM, Won B, Ferguson MK, Patti MG, Posner M, Waxman I, Gordon G, Vokes EE, Salgia R. Genetic alterations in esophageal cancers: Detection by next-generation sequencing and potential for therapeutic targets. Journal of Clinical Oncology. 32: e22065-e22065. DOI: 10.1200/Jco.2014.32.15_Suppl.E22065  0.699
2014 Brand TM, Iida M, Corrigan KL, Luthar N, Hornung M, Toulany M, Gill P, Salgia R, Wheeler DL. Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-215  0.788
2013 Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia (New York, N.Y.). 15: 1196-206. PMID 24204198 DOI: 10.1593/Neo.131584  0.775
2013 Stegeman H, Kaanders JH, Verheijen MM, Peeters WJ, Wheeler DL, Iida M, Grénman R, van der Kogel AJ, Span PN, Bussink J. Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. Molecular Cancer. 12: 133. PMID 24192080 DOI: 10.1186/1476-4598-12-133  0.435
2013 Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discovery Medicine. 16: 79-92. PMID 23998444  0.716
2013 Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. Plos One. 8: e71518. PMID 23951180 DOI: 10.1371/Journal.Pone.0071518  0.708
2013 Stegeman H, Span PN, Rijken PF, Cockx SC, Wheeler DL, Iida M, van der Kogel AJ, Kaanders JH, Bussink J. Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors. Translational Oncology. 6: 413-9. PMID 23908684 DOI: 10.1593/Tlo.13259  0.429
2013 Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 108: 370-7. PMID 23830194 DOI: 10.1016/J.Radonc.2013.06.010  0.782
2013 Wheeler DL, Verma AK, Denning MF. Mouse models of the skin: models to define mechanisms of skin carcinogenesis. Journal of Skin Cancer. 2013: 971495. PMID 23819053 DOI: 10.1155/2013/971495  0.62
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, ... Wheeler DL, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/Cbt.25091  0.708
2013 Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy. 14: 481-91. PMID 23760490 DOI: 10.4161/Cbt.24342  0.775
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/J.Lungcan.2013.03.020  0.72
2013 Stegeman H, Kaanders JH, van der Kogel AJ, Iida M, Wheeler DL, Span PN, Bussink J. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 106: 383-9. PMID 23453541 DOI: 10.1016/J.Radonc.2013.02.001  0.476
2013 Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 32: 759-67. PMID 22430206 DOI: 10.1038/Onc.2012.90  0.768
2013 Brand TM, Iida M, Luthar N, Wleklinski M, Kostopoulos K, Wheeler DL. Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-219  0.774
2013 Iida M, Brand TM, Starr MM, Luthar N, Wleklinski MJ, Wheeler DL. Abstract 5646: Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy. Cancer Research. 73: 5646-5646. DOI: 10.1158/1538-7445.Am2013-5646  0.781
2013 Brand TM, Iida M, Wleklinski MJ, Luthar N, Starr MM, Wheeler DL. Abstract 4276: Mapping C-terminal transactivation domains of nuclear HER family receptor tyrosine kinases. Cancer Research. 73: 4276-4276. DOI: 10.1158/1538-7445.Am2013-4276  0.723
2012 Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grénman R, Span PN, Bussink J. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. Bmc Cancer. 12: 463. PMID 23046567 DOI: 10.1186/1471-2407-12-463  0.5
2012 Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL, Kuo JS. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia (New York, N.Y.). 14: 420-8. PMID 22745588 DOI: 10.1596/Neo.12432  0.545
2012 Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small Gtpases. 3: 34-9. PMID 22714415 DOI: 10.4161/Sgtp.18751  0.749
2012 Li C, Iida M, Huang S, Armstrong EA, Brand TM, Peet CR, Wheeler DL. Abstract 5726: Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas Cancer Research. 72: 5726-5726. DOI: 10.1158/1538-7445.Am2012-5726  0.746
2012 Bussink J, Kaanders J, Wheeler D, van der Kogel A, Iida M, Span P, Stegeman H. PO-0942 EXPRESSION OF THE EGFR/HER2/PAKT PATHWAY IN VITRO AND IN VIVO IS AFFECTED BY HYPOXIA IN HUMAN HEAD AND NECK CANCER Radiotherapy and Oncology. 103: S371. DOI: 10.1016/S0167-8140(12)71275-6  0.44
2012 Stegeman H, Kaanders J, van der Kogel A, Iida M, Wheeler D, Span P, Bussink J. OC-0153 EGFR-INHIBITION AND RADIOTHERAPY IN HEAD AND NECK CANCER XENOGRAFTS: HYPOXIA, PROLIFERATION AND TUMOR GROWTH DELAY Radiotherapy and Oncology. 103: S59. DOI: 10.1016/S0167-8140(12)70492-9  0.447
2012 Stegeman H, Span P, van der Kogel A, Wheeler D, Kaanders J, Bussink J. 61 EFFECTS OF EGFR-INHIBITION AND RADIOTHERAPY ON HYPOXIA, PROLIFERATION AND TUMOR GROWTH DELAY IN HUMAN TUMOR XENOGRAFTS Radiotherapy and Oncology. 102: S21. DOI: 10.1016/S0167-8140(12)70042-7  0.397
2011 Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine. 12: 419-32. PMID 22127113  0.749
2011 Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Research. 71: 7071-9. PMID 22068033 DOI: 10.1158/0008-5472.Can-11-0128  0.488
2011 Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biology & Therapy. 12: 436-46. PMID 21725209 DOI: 10.4161/Cbt.12.5.16394  0.781
2011 Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy. 11: 777-92. PMID 21293176 DOI: 10.4161/Cbt.11.9.15050  0.783
2011 Brand TM, Wheeler DL. Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biology & Therapy. 11: 368-70. PMID 21228636 DOI: 10.4161/Cbt.11.3.14696  0.69
2011 Kruser TJ, Traynor AM, Wheeler DL. The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. Expert Opinion On Investigational Drugs. 20: 305-7. PMID 21204748 DOI: 10.1517/13543784.2011.550873  0.404
2011 Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 30: 561-74. PMID 20956938 DOI: 10.1038/Onc.2010.430  0.484
2011 Brand TM, Dunn EF, Iida M, Myers R, Li C, Wheeler DL. Abstract 726: Erlotinib overcomes acquired resistance to cetuximab Cancer Research. 71: 726-726. DOI: 10.1158/1538-7445.Am2011-726  0.785
2011 Iida M, Campbell DA, Brand TM, Li C, Wheeler DL. Abstract A146: Targeting AKT signaling overcomes acquired resistance to cetuximab in non-small lung cancer cells. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A146  0.765
2010 Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. Plos One. 5: e12702. PMID 20856931 DOI: 10.1371/Journal.Pone.0012702  0.426
2010 Li C, Iida M, Dunn EF, Wheeler DL. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 97: 330-7. PMID 20667610 DOI: 10.1016/S1359-6349(10)71891-7  0.457
2010 Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Reviews. Clinical Oncology. 7: 493-507. PMID 20551942 DOI: 10.1038/Nrclinonc.2010.97  0.527
2010 Kruser TJ, Wheeler DL, Armstrong EA, Iida M, Kozak KR, van der Kogel AJ, Bussink J, Coxon A, Polverino A, Harari PM. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3639-47. PMID 20507929 DOI: 10.1158/1078-0432.Ccr-09-3385  0.375
2010 Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research. 316: 1083-100. PMID 20064507 DOI: 10.1016/J.Yexcr.2010.01.009  0.557
2010 Sand JM, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK. Abstract 5151: Protein kinase Cε, which is linked to development of squamous cell carcinomas, potentiates ultraviolet radiation-induced proliferation of hair follicle putative stem cells Cancer Research. 70: 5151-5151. DOI: 10.1158/1538-7445.Am10-5151  0.788
2010 Li C, Iida M, Dunn E, Wheeler DL. Abstract 338: Enhanced cetuximab and radiosensitization with src inhibition in head and neck cancer Cellular and Molecular Biology. 70: 338-338. DOI: 10.1158/1538-7445.Am10-338  0.335
2010 Dunn E, Iida M, Myers R, Li C, Wheeler D. 172 Molecular mechanisms of the combination treatment of cetuximab and dasatinib in Kras mutant colorectal tumors European Journal of Cancer Supplements. 8: 59. DOI: 10.1016/S1359-6349(10)71877-2  0.331
2010 Iida M, Li C, Brand T, Peet C, Wheeler D. 101 Identification of EGFR regulated genes in cetuximab resistant tumor cell models European Journal of Cancer Supplements. 8: 39. DOI: 10.1016/S1359-6349(10)71806-1  0.734
2010 Kruser T, Wheeler D, Armstrong E, Iida M, Kozak K, van der Kogel A, Bussink J, Coxon A, Polverino A, Harari P. Augmentation of Radiation Response by Motesanib, a Multikinase VEGF Receptor Inhibitor International Journal of Radiation Oncology*Biology*Physics. 78: S115. DOI: 10.1016/J.Ijrobp.2010.07.293  0.323
2009 Hatakeyama H, Parker J, Wheeler D, Harari P, Levy S, Chung CH. Effect of insulin-like growth factor 1 receptor inhibitor on sensitization of head and neck cancer cells to cetuximab and methotrexate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6079. PMID 27961955 DOI: 10.1200/Jco.2009.27.15_Suppl.6079  0.44
2009 Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab Oncogene. 28: 3801-3813. PMID 19684613 DOI: 10.1038/Onc.2009.234  0.58
2009 Wheeler DL, Dunn EF. BB, a novel epidermal growth factor receptor inhibitor. Cancer Biology & Therapy. 8: 1648-50. PMID 19625764 DOI: 10.4161/Cbt.8.17.9358  0.393
2009 Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. The Oncologist. 14: 667-78. PMID 19581523 DOI: 10.1634/Theoncologist.2009-0009  0.501
2009 Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biology & Therapy. 8: 696-703. PMID 19276677 DOI: 10.4161/Cbt.8.8.7903  0.56
2009 Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1585-92. PMID 19190133 DOI: 10.1158/1078-0432.Ccr-08-2068  0.544
2009 Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Seminars in Radiation Oncology. 19: 63-8. PMID 19028347 DOI: 10.1016/J.Semradonc.2008.09.009  0.385
2009 Dunn EF, Iida M, Armstrong E, Wheeler DL. Abstract C43: Dasatinib resensitizes Kras mutant colorectal tumors to cetuximab Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C43  0.479
2008 Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. International Journal of Radiation Oncology, Biology, Physics. 72: 534-42. PMID 18793955 DOI: 10.1016/J.Ijrobp.2008.06.1490  0.453
2008 Wheeler DL, Rangnekar VM, Schwarze SR. ErbB4 targeting approaches for prostate cancer treatment. Cancer Biology & Therapy. 7: 1095-7. PMID 18698169 DOI: 10.4161/Cbt.7.7.6537  0.312
2008 Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members Oncogene. 27: 3944-3956. PMID 18297114 DOI: 10.1038/Onc.2008.19  0.569
2008 Nyflot M, Grudzinski J, Titz B, Armstrong E, Wheeler D, Harari P, Jeraj R. TH-C-351-04: 18F-FLT PET Imaging of Proliferative Response to An EGFR Inhibitor in HNSCC Xenograft Mouse Models Medical Physics. 35: 2975-2975. DOI: 10.1118/1.2962860  0.425
2007 Li Y, Wheeler DL, Ananthaswamy HN, Verma AK, Oberley TD. Differential tumor biology effects of double-initiation in a mouse skin chemical carcinogenesis model comparing wild type versus protein kinase Cepsilon overexpression mice. Toxicologic Pathology. 35: 942-51. PMID 18098040 DOI: 10.1080/01926230701748164  0.631
2007 Wheeler D, Kruser T, Huang S, Armstrong E, Harari P. Acquired Resistance to Cetuximab: Rationale for Sequential Therapies Directed Against the EGFR International Journal of Radiation Oncology*Biology*Physics. 69: S138. DOI: 10.1016/J.Ijrobp.2007.06.007  0.417
2006 Verma AK, Wheeler DL, Aziz MH, Manoharan H. Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer. Molecular Carcinogenesis. 45: 381-8. PMID 16683253 DOI: 10.1002/Mc.20230  0.616
2006 Aziz MH, Wheeler DL, Bhamb B, Verma AK. Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2. Cancer Research. 66: 713-22. PMID 16424000 DOI: 10.1158/0008-5472.CAN-05-2684  0.597
2005 Li Y, Wheeler DL, Alters W, Chaiswing L, Verma AK, Oberley TD. Early epidermal destruction with subsequent epidermal hyperplasia is a unique feature of the papilloma-independent squamous cell carcinoma phenotype in PKCepsilon overexpressing transgenic mice. Toxicologic Pathology. 33: 684-94. PMID 16243773 DOI: 10.1080/01926230500323441  0.621
2005 Wheeler DL, Reddig PJ, Ness KJ, Leith CP, Oberley TD, Verma AK. Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease. The American Journal of Pathology. 166: 117-26. PMID 15632005 DOI: 10.1016/S0002-9440(10)62237-7  0.602
2005 Wheeler DL, Li Y, Verma AK. Protein kinase C epsilon signals ultraviolet light-induced cutaneous damage and development of squamous cell carcinoma possibly through Induction of specific cytokines in a paracrine mechanism. Photochemistry and Photobiology. 81: 9-18. PMID 15458367 DOI: 10.1562/2004-08-12-Ra-271.1  0.656
2004 Wheeler DL, Martin KE, Ness KJ, Li Y, Dreckschmidt NE, Wartman M, Ananthaswamy HN, Mitchell DL, Verma AK. Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas. Cancer Research. 64: 7756-65. PMID 15520180 DOI: 10.1158/0008-5472.Can-04-1881  0.632
2003 Wheeler DL, Ness KJ, Oberley TD, Verma AK. Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice. Cancer Research. 63: 6547-55. PMID 14559850  0.596
2003 Wheeler DL, Ness KJ, Oberley TD, Verma AK. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. Cancer Research. 63: 3037-42. PMID 12810623  0.57
2002 Wheeler DL, Reddig PJ, Dreckschmidt NE, Leitges M, Verma AK. Protein kinase Cdelta-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression. Oncogene. 21: 3620-30. PMID 12032864 DOI: 10.1038/Sj.Onc.1205451  0.641
2001 Jansen AP, Dreckschmidt NE, Verwiebe EG, Wheeler DL, Oberley TD, Verma AK. Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic mice. International Journal of Cancer. 93: 635-43. PMID 11477572 DOI: 10.1002/Ijc.1395  0.769
2001 Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK. Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Research. 61: 808-12. PMID 11221859  0.78
Show low-probability matches.